There are 2934 resources available
Adjuvant therapy or a combination
Presenter: Mario Mandala
Session: Neo-adjuvant vs. adjuvant therapy or combination for locoregional / oligometastatic melanoma
Resources:
Slides
Webcast
2267 - Targeting Molecular Mediators of T cell Exclusion for Effective Immunotherapy in Ovarian Cancer
Presenter: Yulei Wang
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
4983 - Immunogenicity of BRCA1-deficient Ovarian Cancers is Driven through DNA Sensing and is Augmented by PARP Inhibition
Presenter: Marine Bruand
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
2699 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
2434 - Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset
Presenter: Daniel Backenroth
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
2734 - Raman microscopy for the identification of an aggressive variant of prostate cancer, intraductal carcinoma of the prostate
Presenter: Dominique Trudel
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
1983 - Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: a systematic review and meta-analysis
Presenter: Mairead McNamara
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
6093 - BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy. SCAT Trial
Presenter: Bartomeu Massuti
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
5626 - JIPANG study: Randomized Phase III Study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status
Presenter: Masahiro Tsuboi
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
1522 - A Comprehensive Model of Genetic-Features Predicts Outcome of Personalized Adjuvant Treatment in Resected EGFR-mutant Stage II-IIIA NSCLC: Results from a Phase 3 Trial (CTONG 1104-ADJUVANT)
Presenter: Yi-Long Wu
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract